Strong alliance: Nanjing Kingsley biology and Merck reach strategic cooperation in the field of cell and gene therapy

Contract development manufacturing organization (cdmo), the world's leading biomedical contract R & D and production company, Nanjing Kingsley biotechnology and Merck, the world's leading technology company, jointly announced today that the two sides have launched all-round strategic cooperation in the field of cell gene therapy for the first time, jointly promoting the industrialization process of cell immune and gene therapy industries According to the content of the agreement, Merck will provide Kingsley with 360 degree services in the production of plasmid virus, including products, process technology, plant design consultation, quality system establishment, GMP compliance consultation, personnel training, etc., to help Kingsley build the plasmid and virus carrier production service platform and international strategy The two companies will cooperate fully in plasmid virus quality system and GMP compliance, process and plant design and market promotion As a cdmo company that has helped Nanjing legend complete clinical application in the field of cell therapy, Kingsley has a GMP workshop designed and built based on the requirements of cGMP in the United States, Europe and China, and a mature process quality research platform The strategic agreement signed by Kingsley and Merck aims to integrate all internal resources, maximize the interests of customers, and through long-term strategic cooperation between the two companies So that both sides can achieve win-win results and grow together Group photo of all the staff: "at present, cell gene therapy is developing rapidly in the world, while the commercialization of cell gene therapy is facing many challenges." at the signing ceremony, Mr Wang Dongliang, vice president of operation of Kingsley biomedical business department, first treated the whole cell gene therapy The current situation and market trend of the field were analyzed and said: "we are very happy to carry out strategic cooperation with Merck With the excellent cGMP production facilities jointly built with Merck, we can better serve local and overseas customers, so as to achieve our mission to help customers accelerate the commercialization process "Producing high-quality plasmids and virus vectors is a key link in the commercialization of cell and gene therapy," said udit batra, member of Merck's executive board and chief executive officer of life sciences "Merck is the largest virus vector in the world One of the manufacturers, this cooperation will give Kingsley nearly 30 years of experience in gene and cell therapy production " Ms Wang Muyang, general manager of Merck's life science process solutions in China, and Mr Benoit opsomer, vice president of Merck's life science process and head of Asia Pacific region, attended the signing ceremony and delivered a speech Mr Benoit opsomer, vice president of Merck's life science biotechnology and head of Asia Pacific region, delivered a speech, and Ms Wang Muyang, general manager of Merck's life science technology solutions in China, delivered a speech After the signing ceremony, Mr Wang Dongliang, vice president of operation of Kingsley's biopharmaceutical business unit, Mr Wei Shigang, vice director of plasmid virus process development department, Mr Benoit opsomer, vice president of Merck's life science bioprocess and head of Asia Pacific Region ）Mr Wang and Ms Wang Muyang, general manager of Merck's life science process solutions in China, have been interviewed by three media, i.e the first financial daily, yimaike, and medicine Rubik's cube The detailed interview content will be released in the future About Kingsley bio, Kingsley is China's leading biomedical contract R & D and production organization (cdmo), which has a customized platform for gene synthesis, peptide synthesis, antibody development, protein expression and other biological reagents, as well as a one-stop biomedical R & D platform Kingsley has a one-stop development solution for antibody drugs, covering antibody drug discovery services (hybridoma technology, phage display technology, all human technology, double specific antibody technology), antibody engineering (humanization, drug evaluation and optimization, affinity maturity), etc Kingsley's overall cell therapy solution covers the writing of ind application materials, clinical sample production and commercial production The development control of production process ensures compliance, the records are true and complete to ensure traceability, and all test deviations are strictly studied and recorded Kingsley always takes "providing the best quality to customers and serving the interests of customers" as the concept, and is committed to helping customers shorten the time for bio innovative drugs to enter clinical practice, significantly reduce the cost of customer research and development, accelerate the transformation of medicine, build a healthy future, and help 2025 "made in China" about Merck Merck is a leading technology company, focusing on three major areas of medical health, life sciences and high-performance materials Around 52000 employees around the world serve Merck and are committed to promoting technological progress and improving people's lives, ranging from biotherapy for cancer and multiple sclerosis, to cutting-edge systems for scientific research and production, to liquid crystal materials for smartphones and flat-panel TVs In 2018, Merck's total sales in 66 countries reached 14.8 billion euros Merck is the world's oldest pharmaceutical and chemical company As the founder of the company, Merck family still holds most shares of Merck The company is one of the 30 largest German companies in Frankfurt Stock Exchange Merck, based in Darmstadt, Germany, owns the name and brand of "Merck" in the world, with the only exceptions in Canada and the United States, where Merck uses the names EMD Serono, millipore Sigma and EMD performance materials.